home.social

#tumorimmunology — Public Fediverse posts

Live and recent posts from across the Fediverse tagged #tumorimmunology, aggregated by home.social.

  1. 'We have previously demonstrated that excising transcription factor Kruppel-like factor 2 (Klf2) within the T cell lineage blocks the generation of peripheral-derived Tregs (pTregs) without impairing production of thymic-derived Tregs. Using this mouse model, we have now demonstrated that eliminating pTregs is sufficient to delay/prevent tumor malignancy without causing autoimmunity.'
    #Immunology #TumorImmunology #Tregs #Immunotherapy

    pnas.org/doi/10.1073/pnas.2404

  2. 'In this issue of Nature Medicine, Cascone et al.2share the latest results of their phase 2 platform trial, NEOSTAR, which suggest that the addition of CTLA-4 blockade to neoadjuvant anti-PD-1 plus chemotherapy may augment anti-tumor responses.'

    #LungCancer #Immunology #TumorImmunology #immunotherapy #checkpointinhibitors

    nature.com/articles/s41591-023

  3. New publication alert in Cancer Discovery (@[email protected]) of a study my colleagues of Lead Pharma and I were involved in! Discovery of Targets for Immune–Metabolic Antitumor Drugs Identifies Estrogen-Related Receptor Alpha; see aacrjournals.org/cancerdiscove, in cooperation with Avinash Sahu, Xiaoman Wang, @[email protected], @[email protected], Keith Flaherty et al, and my colleagues and me at Lead Pharma. #cancerresearch #cancer #tumorimmunology #targetdiscovery #drugdevelopment #immunometabolism #tumormetabolism

  4. "Differing from its predecessor, ENLIGHT has been designed and evaluated with two real-world clinical scenarios in mind: personalized oncology, where one matches the best treatment to a patient based on a fixed decision threshold, and CTD, where the goal is to a priori exclude non-responding patients in the best possible manner. "

    #immunotherapy #Immunology #TumorImmunology #Biomarker #PersonalisedMedicine

    cell.com/med/fulltext/S2666-63